Cutaneous Leishmaniasis: The Complexity of Host's Effective Immune Response against a Polymorphic Parasitic Disease.

Cutaneous Leishmaniasis: The Complexity of Host's Effective Immune Response against a Polymorphic Parasitic Disease. J Immunol Res. 2019;2019:2603730 Authors: Gabriel Á, Valério-Bolas A, Palma-Marques J, Mourata-Gonçalves P, Ruas P, Dias-Guerreiro T, Santos-Gomes G Abstract This review is aimed at providing a comprehensive outline of the immune response displayed against cutaneous leishmaniasis (CL), the more common zoonotic infection caused by protozoan parasites of the genus Leishmania. Although of polymorphic clinical presentation, classically CL is characterized by leishmaniotic lesions on the face and extremities of the patients, which can be ulcerative, and even after healing can lead to permanent injuries and disfigurement, affecting significantly their psychological, social, and economic well-being. According a report released by the World Health Organization, the disability-adjusted life years (DALYs) lost due to leishmaniasis are close to 2.4 million, annually there are 1.0-1.5 million new cases of CL, and a numerous population is at risk in the endemic areas. Despite its increasing worldwide incidence, it is one of the so-called neglected tropical diseases. Furthermore, this review provides an overview of the existing knowledge of the host innate and acquired immune response to cutaneous species of Leishmania. The use of animal models and of in vitro studies has improved the understanding of parasite-host interplay and the ...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research

Related Links:

ConclusionsNatalizumab is highly effective as measured by the NEDA long-term remission parameter.ResumenIntroducciónLa efectividad y seguridad de natalizumab en pacientes con esclerosis múltiple remitente recurrente (EMRR) se demostró en ensayos clínicos. Sin embargo, por las limitaciones de estos, es importante saber cómo se comporta en condiciones de práctica clínica a largo plazo.ObjetivoConocer la eficacia a largo plazo de natalizumab en pacientes con EMRR mediante la evaluación anual del NEDA (no evidence of disease activity), que incluye número de brotes,...
Source: Neurologia - Category: Neurology Source Type: research
AbstractThis guideline aims to describe the complement system and the functions of the constituent pathways, with  particular focus on primary immunodeficiencies (PIDs) and their diagnosis and management. The complement system is a crucial part of the innate immune system, with multiple membrane-bound and soluble components. There are three distinct enzymatic cascade pathways within the complement system, the classical, alternative and lectin pathways, which converge with the cleavage of central C3. Complement deficiencies account for ~5% of PIDs. The clinical consequences of inherited defects in the complement system...
Source: Journal of Clinical Immunology - Category: Allergy & Immunology Source Type: research
AbstractAerophagia is a functional gastrointestinal disorder characterized by excessive swallowing of air associated with abdominal distension and pain, flatulence, belching, nausea, and vomiting. The purpose of the current study was to evaluate the effectiveness of an antecedent-based behavioral intervention on aerophagia with an adolescent female diagnosed with Lennox-Gastaut syndrome (LGS), severe intellectual disability, and herpes simplex virus infection of the central nervous system with chronic static encephalopathy. Results from a functional analysis and multiple-component aerophagia assessment suggested that aerop...
Source: Journal of Developmental and Physical Disabilities - Category: Disability Source Type: research
AbstractThe Vi polysaccharide typhoid fever vaccine (TFV) provides incomplete protection against typhoid fever. BCG, the vaccine against tuberculosis, can potentiate immune responses to other vaccines through induction of trained innate immunity and heterologous adaptive immunity. We performed an explorative, randomized, noncontrolled open trial to investigate whether BCG vaccination increases humoral and cellular response to TFV and whether BCG and TFV modulate nonspecific immune responses. Thirty volunteers were randomized to receive either TFV alone or BCG followed by TFV after 2  weeks. Ex vivo leukocyte responses...
Source: European Journal of Clinical Microbiology and Infectious Diseases - Category: Microbiology Source Type: research
We present the current portfolio of next-generation anti-Wolbachia candidates discovered through phenotypic screening of chemical libraries and validated in a range of in vitro and in vivo filarial infection models. Several novel chemotypes have been identified with selected narrow-spectrum anti-Wolbachia specificity and superior time-to-kill kinetics compared with doxycycline. We discuss the opportunities of developing these novel anti-Wolbachia agents as either cures, adjunct therapies or new preventatives for the treatment of veterinary filariasis.
Source: Veterinary Parasitology - Category: Veterinary Research Source Type: research
CONCLUSIONS: The results indicate that, although persons with disabilities can exhibit a wide functional range, they remain at risk of PUs and should be evaluated for proper preventive measures, including support surfaces and wheelchair cushions. PMID: 32058440 [PubMed - in process]
Source: Adv Data - Category: Epidemiology Authors: Tags: Adv Skin Wound Care Source Type: research
Discussion of the Evolutionary Genetics of Aging Thymic Involution Contributes to Immunosenescence and Inflammaging The Potential for Exosome Therapies to Treat Sarcopenia Correlations of Mitochondrial DNA Copy Number and Epigenetic Age Measures Evidence for PASK Deficiency to Reduce the Impact of Aging in Mice The Aging Retina, a Mirror of the Aging Brain Evidence for Loss of Capillary Density to be Important in Heart Disease Aspects of Immune System Aging Proceed More Rapidly in Men Deacetylation of the NLRP3 Inflammasome as a Way to Control Chronic Inflammation Transplantation of Senescent Cells is an ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: Available online 16 February 2020Source: Life SciencesAuthor(s): Shima Bastaki, Mahzad Irandoust, Armin Ahmadi, Mohammad Hojjat-Farsangi, Patrick Ambrose, Shahin Hallaj, Mahdi Edalati Fathabad, Ghasem Ghalamfarsa, Gholamreza Azizi, Mehdi Yousefi, Hengameh Chalajour, Farhad Jadidi-NiaraghAbstractAlthough both the incidence and the mortality rate of breast cancer is rising, there is no potent and practical option for the treatment of these patients, particularly in advanced stages. One of the most critical challenges for treatment is the presence of complicated and extensive tumor escape mechanisms in the t...
Source: Life Sciences - Category: Biology Source Type: research
Authors: Graul AI, Pina P, Tracy M, Sorbera L Abstract Highlights of our annual review of new approvals and launches on global drug markets include the approval and launch of Trikafta, the most widely applicable treatment to date for cystic fibrosis; approval of the first Ebola vaccine for general (rather than emergency) use; the pilot rollout in three African countries of the world's first malaria vaccine; approval of a new treatment option for multidrug-resistant bacterial infections; and the approval and launch in China of the first new drug to treat Alzheimer's disease in more than a decade. Several new immune ...
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
Authors: Gajofatto A, Turatti M Abstract Siponimod fumarate (BAF-312) is a synthetic sphingosine 1- phosphate (S1P) receptor modulator, which exerts immunomodulating effects mediated by B- and T-cell sequestration in secondary lymphoid organs. S1P receptor modulators have consistently shown a significant benefit on relapse rate and other measures of disease activity in patients with relapsing multiple sclerosis (MS), compared with both placebo and active comparator. However, most clinical trials of S1P receptor modulators--as well as other therapies for MS--lack evidence of a significant benefit on disability progr...
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
More News: Allergy & Immunology | Disability | Endemics | HIV-Leishmania Co-infection | International Medicine & Public Health | Parasitic Diseases | Parasitology | Psychology | Study | Vaccines | Veterinary Vaccinations | WHO | Zoonoses